These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35211947)

  • 1. [Adverse effects and complications of continuous intestinal infusion of levodopa-carbidopa in a cohort of patients with Parkinson's disease in a tertiary hospital].
    Campins-Romeu M; Sastre-Bataller I; Pons-Beltrán V; Baviera-Muñoz R; Losada-López M; Morata-Martínez C; Pérez-García J; Martínez-Torres I
    Rev Neurol; 2022 Mar; 74(5):143-148. PubMed ID: 35211947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
    Blaise AS; Baille G; Carrière N; Devos D; Dujardin K; Grolez G; Kreisler A; Kyheng M; Moreau C; Mutez E; Seguy D; Defebvre L
    Rev Neurol (Paris); 2020 May; 176(4):268-276. PubMed ID: 31668287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
    Udd M; Lyytinen J; Eerola-Rautio J; Kenttämies A; Lindström O; Kylänpää L; Pekkonen E
    Brain Behav; 2017 Jul; 7(7):e00737. PubMed ID: 28729942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
    Lang AE; Rodriguez RL; Boyd JT; Chouinard S; Zadikoff C; Espay AJ; Slevin JT; Fernandez HH; Lew MF; Stein DA; Odin P; Fung VS; Klostermann F; Fasano A; Draganov PV; Schmulewitz N; Robieson WZ; Eaton S; Chatamra K; Benesh JA; Dubow J
    Mov Disord; 2016 Apr; 31(4):538-46. PubMed ID: 26695437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
    Fernandez HH; Boyd JT; Fung VSC; Lew MF; Rodriguez RL; Slevin JT; Standaert DG; Zadikoff C; Vanagunas AD; Chatamra K; Eaton S; Facheris MF; Hall C; Robieson WZ; Benesh J; Espay AJ
    Mov Disord; 2018 Jul; 33(6):928-936. PubMed ID: 29570853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal burying of the jejunal-tube of a PEG-J levodopa-carbidopa release system for Parkinson's disease. Successful endoscopic management.
    Moralejo Lozano Ó; Barrajón Masa AJ; Colmenares Bulgheroni M
    Rev Esp Enferm Dig; 2021 Mar; 113(3):226-227. PubMed ID: 33207895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
    Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
    J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
    Nyholm D; Odin P; Johansson A; Chatamra K; Locke C; Dutta S; Othman AA
    AAPS J; 2013 Apr; 15(2):316-23. PubMed ID: 23229334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
    Meloni M; Solla P; Mascia MM; Marrosu F; Cannas A
    Parkinsonism Relat Disord; 2017 Apr; 37():92-96. PubMed ID: 28063683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
    Fabbri M; Zibetti M; Beccaria L; Merola A; Romagnolo A; Montanaro E; Ferreira JJ; Palermo S; Lopiano L
    Eur J Neurol; 2019 Mar; 26(3):490-496. PubMed ID: 30347489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
    Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.
    Marano M; Naranian T; di Biase L; Di Santo A; Poon YY; Arca R; Cossu G; Marano P; Di Lazzaro V; Fasano A
    Parkinsonism Relat Disord; 2019 Dec; 69():140-146. PubMed ID: 31759188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
    Bohlega S; Abou Al-Shaar H; Alkhairallah T; Al-Ajlan F; Hasan N; Alkahtani K
    Eur Neurol; 2015; 74(5-6):227-36. PubMed ID: 26618531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single-center long-term follow-up study.
    Rus T; Premzl M; Križnar NZ; Kramberger MG; Rajnar R; Ocepek L; Pirtošek Z; Trošt M
    Acta Neurol Scand; 2022 Nov; 146(5):537-544. PubMed ID: 35903042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
    Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
    Nyholm D; Klangemo K; Johansson A
    Eur J Neurol; 2012 Aug; 19(8):1079-85. PubMed ID: 22360705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
    Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
    J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.